![Page 1: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/1.jpg)
What’s New in Lupus?
Jeffrey Carlin, MDSection Head,
Division of RheumatologyVirginia Mason Medical Center
Clinical Associate ProfessorUniversity of Washington
![Page 2: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/2.jpg)
Key Points
• Diagnosing Lupus– ANA testing
• Treatment Options• New Therapeutic Agents• Adjuvant Therapy
![Page 3: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/3.jpg)
Lupus Demographics
USA Incidence(per 100,000per year)
Prevalence(per 100,000)
All 5.1 52.2
White 1.4 7.4
Black 4.5 19.5
Puerto Rican
2.2 18.0
Danchenko N et al Lupus 2006:308-318
Incidence and Prevalence of SLE:
Rochester, MN
Uramoto KM et al Arth Rheum 1999;46-50
![Page 4: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/4.jpg)
SLE - Etiology• The etiology of SLE remains unknown• Yet, SLE is clearly multifactorial:
– Genetic factors– Immunologic factors– Hormonal factors– Environmental factors
EBV?
Genetic predisposition
InfectionAbnormal (control of) immune responses
Hormonal factors
Baseline immunological abnormalities
SLE
![Page 5: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/5.jpg)
Interferon-α Stimulation
Ronneblom L, Alm GV Arth Res Ther 2003;68-75
![Page 6: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/6.jpg)
Evironmental Triggers of SLE
• UV Light• Drugs (>100 Identified)• Smoking• Infections
– Pet Dogs– Lab workers– EBV
• Silica• Mercury
![Page 7: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/7.jpg)
When Does Lupus Begin?
Arbuckle M, et al NEJM 2003
![Page 8: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/8.jpg)
Stages in Development of Pathogenic Autoimmunity
![Page 9: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/9.jpg)
ANA Techniques
![Page 10: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/10.jpg)
Frequencies of Positive ANA’s in Normal individuals
Pooled ANA DataHep-2 Cell Lines
68.3
31.7
13.3
5 3.3
0
10
20
30
40
50
60
70
80
Negative 1:40 1:80 1:160 1:320Fluorescence/Dilution Level
Per
cen
tag
e
Tan E.M., et al Arthritis and Rheum 1997
![Page 11: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/11.jpg)
Estimated Prevalence of ANA + in the US Population
Satoh M et al Arth & Rheum 2012;64:2319-2127
![Page 12: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/12.jpg)
Positive ANA
High Probability of
CTD
IdentifySpecific
ANA Antigen
Search for OtherEvidence of Disease Or Organ Involvement
Consider AncillaryLab Tests
Low Probabilityof
CTD
Low TiterANA
High Titer ANA
FollowPt
ReassurePt Search for Other
Evidence of Disease Or Organ Involvement
IdentifySpecific Antigen
![Page 13: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/13.jpg)
Remember!
A positive ANA does not mean the patient has a connective tissue disease, but a negative ANA will R/O CTD
![Page 14: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/14.jpg)
Lab investigations• Screen- CBC, urinanalysis & serum creatinine• Anti ds DNA
• In about 60% with SLE• Levels often reflect disease activity• with Rx ( ANA remains +)• If normal – safe to Rx in chronic phase
• ENA’s• complement
• In ¾ untreated esp. with nephritis• APLA
In 1/3 to ½Associated with renal arterial, venous & glomerular thrombosis
![Page 15: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/15.jpg)
Anti-Ds DNA AntibodyAnti- Histone Antibody
Antibodies directed against exposed parts of the Nucleosome
![Page 16: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/16.jpg)
Anti-ds DNA Antibodies
• Large literature suggesting these are strong biomarkers
• Used widely in clinical practice– High Titer IgG anti-dsDNA predict nephritis
• But not in immediate future!
– High Affinity anti-dsDNA associated with flare– Glomerular IC enriched for anti-dsDNA
![Page 17: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/17.jpg)
Extractable Nuclear Antigens(ENA’S)
• Autoantibodies against nuclear ribonucleoproteins/nuclear components– SSA, SSB, Sm, RNP, anti-Histone
• ELISA assays• Useful for helping to confirm diagnosis
– used as adjunct to ANA• Not useful for disease monitoring
– need not be repeated once identified
![Page 18: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/18.jpg)
Anti-U1 SnRNP Antibodies
Anti-RNP Ab
Anti-Sm Ab
![Page 19: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/19.jpg)
Antigen SLE Drug-Induced
Native DNA 40% No
Denatured DNA 70% 75-80%
Histones 70% >95%
SM Antigen 30% No
Nuclear RNP 30% No
Ribosomal RNP 10%
SSA/Ro 35% No
SSB/La 15% No
Prevalence of Autoantibodies in SLE
![Page 20: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/20.jpg)
Antigen SLE Clinical Associations
Native DNA 40% Nephritis (and flare)
Denatured DNA 70% Non-Specific
Histones 70% Drug-Induced Lupus
SM Antigen 30% Severe SLE
Nuclear RNP 30% Arthritis
Ribosomal RNP 10%
SSA/Ro 35% SCLE, Sjogren’s NLS
SSB/La 15% SCLE, Sjogren’s NLS
Significance of Autoantibodies in SLE
![Page 21: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/21.jpg)
Antibody Clustering in SLE
• Cluster 1 - anti-Sm/RNP Ab’s– Primarily skin involvement– Less proteinuria, anemia, thrombocytopenia
• Cluster 2 - anti-dsDNA/SSA/SSB Ab’s– Highest incidence of renal disease– Secondary Sjogren’s
• Cluster 3 -anti-dsDNA/LAC/ACL Ab’s– Arterial/Venous thrombosus, livedo reticularis– Highest incidence of CVA’s
Hopkins Lupus Cohort Study -1,357 patients Average follow-up 9.6 years
To CH, Petri M Arthritis and Rheum 2005
![Page 22: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/22.jpg)
ACR SLE Classification Criteria(SOAP BRAIN MD)
1. Serositis: (a) pleuritis, or (b) pericarditis
2. Oral ulcers3. Arthritis4. Photosensitivity
10. Malar rash11. Discoid rash
5. Blood/Hematologic disorder: (a) hemolytic anemia or(b) leukopenia of < 4.0 x 109 (c) lymphopenia of < 1.5 x 109 (d) thrombocytopenia < 100 X
109
6. Renal disorder: (a) proteinuria > 0.5 gm/24 h or 3+ dipstick or(b) cellular casts
7. Antinuclear antibody (positive ANA) 8. Immunologic disorders:
(a) raised anti-native DNA antibody binding or(b) anti-Sm antibody or (c) positive anti-phospholipid antibody work-up
9. Neurological disorder: (a) seizures or (b) psychosis
". ..A person shall be said to have SLE if four or more of the 11 criteria are present, serially or simultaneously, during any interval of observation."
![Page 23: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/23.jpg)
SLICC Criteria for Lupus• Acute Cutaneous
– Malar rash, subacute cutaneous lupus rash, bullous lupus
• Chronic Cutaneous– Discoid Lupus, Lupus
panniculitis• Oral/Nasal Ulcers• Non-scarring Alopecia• Synovitis• Serositis
• Renal– Urine protein/creat ratio >
500mg/24 hrs or active renal sediment
• Neuro– Sz, pyschosis, myelitis,
mononeuritis, peripheral neuropathy
• Heme– Hemolytic anemia, neutropenia,
lymphopenia thrombocytopenia• Immunological
– ANA, DNA, Sm, Low Complements, Coombs +, Antiphospholipid Ab’s
Petri M et al, Arth & Rheum 2012; 64: 2677–2686
![Page 24: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/24.jpg)
Performance of SLICC Criteria
1997 ACR Criteria 2012 SLICC Criteria
Sensitivity 2907349 (83%) 340/349(97%)
Specificity 326/341 (96%) 288/341(84%)
Misclassified cases 74 62
Petri M et al, Arth & Rheum 2012; 64: 2677–2686
![Page 25: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/25.jpg)
Clinical Features on Presentation in SLE
• Arthritis or Arthralgia 55%• Skin Involvement 20%• Nephritis 5%• Fever 5%• Other 15%
![Page 26: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/26.jpg)
Organ Involvement in the Course of SLE
– Joints 90%– Skin
• Rashes 70%– Discoid Lesions 30%– Alopecia 40%
– Pleurisy/Pericarditis 60%– Kidney 50%– Raynaud’s 20%– Mucous Membranes 15%– CNS (Seizures/Psychosis/CVA) 15%
![Page 27: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/27.jpg)
50% Patients Have Organ Damage In the Course of Disease
24.2%15.0%12.6%11.7%10.4%10.1% 7.4% 7.4% 5.5% 6.1% 2.5% 1.2%
MusculoskeletalNeuropsychiatricOcularRenalPulmonaryCardiovascularGastrointestinalSkinPeripheral VascularDiabetes MellitusMalignancyPremature Gonadal Failure
![Page 28: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/28.jpg)
Malar Rash- Note Sparing of Nasolabial Folds
Acute Cutaneous
![Page 29: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/29.jpg)
Discoid Lupus
Chronic Cutaneous: DiscoidNote Scarring, Hyperpigmentation
Follicular Plugging
![Page 30: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/30.jpg)
Which patient has SLE?
![Page 31: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/31.jpg)
Subacute Cutaneous Lupus
Annular eruptionPapular squamous eruption
![Page 32: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/32.jpg)
Livedo Reticularis
![Page 33: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/33.jpg)
Non-specific Skin Manifestations
Raynaud’s with tissue breakdown
Vasculitis
![Page 34: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/34.jpg)
Jaccoud’s Arthopathy: Nonerosive, Reducible Deformities
Nodules Possible
Joint Disease in SLE
![Page 35: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/35.jpg)
DX Antibodies Clinical Features
APS ACL, antiB2GP1, LA
Thrombosis inflammation
ITP anti-IIb/IIIa, PF4 Bleeding <20KThrombosis
Hemolytic Anemia
Coomb’s + Hemolysis
TTP VWB multimer proteaseantibodies
Catastrophic APSHELLP SyndromeTTP of SLE
Bleeding anti-FVIII (IX, X!, XII, XIII)
Hematomas, HematuriaGI/mucosal bleeds
Severe Hematologic Syndromes of SLE
![Page 36: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/36.jpg)
Anti-Cardiolipin Antibody Syndrome• Recurrent arterial or venous events• Obstetrical
– Recurrent miscarriages/fetal growth retardation• Thrombocytopenia• Incidence of + Antibodies in SLE
– LAC -30%– ACL- 23-27%– Anti- B2 Glycoprotein 1 - 20%
• 2 + tests 12 weeks apart to confirm diagnosis!
![Page 37: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/37.jpg)
Lupus NephritisClass I: normal glomeruli (~8% of biopsies) Class II: pure mesangial alterations (~40% of biopsies) Class III: focal glomerulonephritis (~15% of biopsies) Class IIIA: focal segmental glomerulonephritis (~12%
of biopsies) Class IIIB: focal proliferative glomerulonephritis Class IV: diffuse glomerulonephritis (~25% of biopsies) Class V: diffuse membranous glomerulonephritis (~8% of
biopsies) Class VI: advanced sclerosing glomerulonephritis
![Page 38: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/38.jpg)
![Page 39: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/39.jpg)
Prognosis in Lupus Nephritis
• Predictors of poor prognosis:– Black race– Male– Anemia– creatinine– Nephrotic range proteinuria– Glomerular & tubulointerstitial scarring – Severe tubulointerstitial nephritis– Chroniciy index > 3
![Page 40: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/40.jpg)
ACR NOMENCLATURE AND CASE DEFINITIONS FOR NEUROPSYCHIATRIC LUPUS SYNDROMES
Central nervous systemAseptic meningitisCerebrovascular diseaseDemyelinating syndromeHeadache (including migraine and benign intracranial hypertension)Movement disorder (chorea)MyelopathySeizure disordersAcute confusional stateAnxiety disorderCognitive dysfunctionMood disorderPsychosis
ARTHRITIS & RHEUMATISM 1999, pp 599-608
![Page 41: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/41.jpg)
Prevalence of 12 NP Clinical Syndromes in CNS lupus (N=300)
• Headache 24%• CVA 18%• Mood disorder 17%• Cognitive dysfunction 11%• Psychosis 8%• Seizure disorder 8%• Anxiety Disorder 7%• Aseptic meningitis 4%• Acute confusional state 4%• Transverse myelopathy 1%• Movement disorder 1%• Demyelinating syndrome 1%
Sanna G, et al Journal of Rheumatology 2003:30;985-992
![Page 42: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/42.jpg)
Diagnostic Studies in CNS Lupus• CT• MRI• SPECT• PET• MRA• CT angiogram• Conventional angiograms• CSF analyses
– Cells– Protein– Oligoclonal bands– IgG/albumin index– Cytokines
• EEG• Neuropsychological testing• Anti-neuronal antibodies (e.g. ribosomal-P, neurofilimant,
NR2 NMDA glutamate receptor)
![Page 43: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/43.jpg)
Current Goals of Rx with SLE
• Control daily symptoms that decrease quality of life
• Manage acute periods of potentially life-threatening or organ threatening involvement
• Minimize risk of life-threatening disease flare-ups during periods of disease stabilization
![Page 44: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/44.jpg)
Treatment• Hydroxychloroquine• Corticosteroids• ASA• NSAIDS• Azathioprine• MTX/Leflunomide• Mycophenolate Mofetil• Cyclophosphamide• Anticoagulants• Biologics
RX For SLEREQUIRESA DISCLAIMER
![Page 45: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/45.jpg)
EULAR Treatment Guidelines:General Management
• Antimalarials and/or Glucocorticosteroids– Use in pts w/o major organ manifestations
• NSAID’s– Use judiciously for limited period of time in pts at low risk
of complications with this drug class• Immunosuppressive Rx
– Use in non-responsive pts or in pts where dose of corticosteroids cannot be decreased to acceptable doses for chronic use
![Page 46: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/46.jpg)
Anti-malarials• All patients should be on Rx if tolerated
– 2 studies show decrease frequency of major/minor flares– Mild anti-platelet effect– Beneficial cholesterol effects
• Useful for skin/joint/pleurisy/pericarditis• Hydroxychloroquine safer than Chloroquine
– Eye evaluation every 6 month-year• Atabrine does not cause eye toxicity but can cause
yellow skin
![Page 47: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/47.jpg)
Hydroxychlorquine Reduces Organ Damage
Fessler B, et al Arth & Rheum 2005;1473-1480
![Page 48: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/48.jpg)
Hydroxychloroquine in Lupus Pregnancy
• No HCQ exposure during pregnancy (N=163)• Continuous use of HCQ during pregnancy (N=56) • Cessation of HCQ treatment either in the 3 months prior to or
during the first trimester of pregnancy (N=38) • Results
– No difference in congenital abnormalities, stillborns miscarriages
– Higher incidence of Lupus Activity and Flare in Non-users
Clowse, M et al A & R 2006:54; 3640-3647
![Page 49: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/49.jpg)
Immunosuppressives
• Methotrexate-(+ Hydroxychloroquine)– 7.5-25mg/week– Best for arthritis
• Azathioprine- (+ Hydroxychloroquine)– Check TMPT assay pre-rx– Useful for joint/skin/nephritis– 3-6 months for effect
![Page 50: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/50.jpg)
Immunosuppressive II
• Leflunomide- (+ Hydroxychloroquine)– 3rd line for joint/skin/nephritis– Very tetragenic
• Mycophenylate– Use for nephritis– 3rd line for skin/joint
![Page 51: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/51.jpg)
Mycophenolate Mofetil
• Hydrolyzed to active form: Mycophenolic acid• Inhibits Inosine Monophosphate Dehydrogenase: Blocks purine
synthesis• Affects activated/dividing lymphocytes• Originally developed to prevent allograft rejection• Dosed: 500 Mg PO BID – 1.5g PO BID
![Page 52: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/52.jpg)
Remission rates: MMF vs IVC
0
10
20
30
40
50
60
Complete Remission Partial Remission Complete + PartialRemission
MMF IVC
16/71
4/69
21/7117/69
37/71
21/69
Intent-to-Treat analysis
p = NSp = 0.005
p = 0.009
Res
po
nd
ing
(%
)
Ginzler, E. et al., N Engl J Med 2005;353:2219-28
![Page 53: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/53.jpg)
Induction Rx of Lupus Nephritis
Oral MMF IV CTX P value Randomized/Rx’d 71/71 69/66 Study Endpoint 66 64 Completed 24 wks Rx 56 42 0.017 Complete Remission 16 4 0.005 Treatment Failure 34 48 0.01 Death 0 3 UGI Toxicity 23 25 Hematologic Toxicity 21 31 Infection/Serious 40/1 56/6
Ginzler E et al NEJM; 353:2219-28
![Page 54: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/54.jpg)
Belimumab Mechanism of Action
![Page 55: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/55.jpg)
Slow onset
Lancet 2011
![Page 56: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/56.jpg)
Belimumab
Reduction in Steroid Dose
Time to Flare
![Page 57: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/57.jpg)
Belimumab Improved or Stabilized SLE Disease Activity and Reduced Flare Rate during 3 Years
of Therapy
Furie Eular 2008; Merrill ACR 2011 6 year data
0%
20%
40%
60%
80%
52 wkPBO
52 wk 76 wk 128 wk 160 wk
Per
cent
Fla
re
SS flares
Severe SS flare
![Page 58: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/58.jpg)
Belimumab (Benlysta)
• 1st new drug for SLE in 50 yrs• Pts most appropriate for rx have musculoskeletal,
cutaneous, immunological disease despite standard of care– Not studied in CNS or renal disease– Unknown effect in African Americans
• Side effects– Hypersensitiviy reactions– Low risk of serious infections– Depression
![Page 59: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/59.jpg)
SLE Rx AlgorithmSLE Severity
Mild• Skin
Manifestations• Arthritis
Moderate• Mild/Moderate Nephritis• Thrombophlebitis• Major Serositis
Induction RxIV MMF x3 days followed by:
AZA (2mg/kg/d) or MMF 2-3 gms/d+
Prednisone .5 mg/kg x 4-6 wk, then taper
RxHCQ or MTX
+ Prednisone
Severe• Severe Nephritis
(Class 4 or 5 with renal impairment)
• Severe refractory thrombocytopenia/hemolytic anemia
• Pulmonary hemorrhage• CNS disease• Vasculitis
Induction RxIV MMF
Or CTX( 750 mg/m2)
+IV CYC 1 gm x3 d
Maintenance RxCTX 750mg/m2/mo x 6mo
or MMF 2-3 gm/day
+Prednisone Taper
MaintenanceAZA or MMF
+Steroid Taper
+(?)Belimumab
![Page 60: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/60.jpg)
EULAR SLE Treatment Guidelines:Adjuvant Therapy
• Photoprotection– May be helpful in skin manifestations
• Estrogens– BCP’s/ERT’s can be used, but accompanying risks should
be assessed• Lifestyle modifications
– Smoking cessation, wgt loss, exercise likely to be helpful• Other Agents
– Statins, Bisphophonates, Ca/Vit D, low dose ASA, anti-hypertensives (including ACE inhibitors) should be considered depending upon situation
![Page 61: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/61.jpg)
![Page 62: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/62.jpg)
Lupus Mortality
• Early Mortality– Infections– Lupus-related
• Late Mortality– Cardiovasular Disease– Malignancies
![Page 63: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/63.jpg)
Proposed Care Pathway for Management of SLE Patients
Registration of pts with SLE
Screening for risk factors
Assessment of clinical manifestations
Management for individual risk factors as per guidelines
Known CHD
No known CHD BMI <25kg/m2
BMI > 25kg/m2 Wgt Reduction
?Steroid Adjustment
Individual risk factor mgmt
BP
Cholesterol
Diabetes
Wajed J et al Rheumatology 2003
![Page 64: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/64.jpg)
Thank You!
![Page 65: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/65.jpg)
Mortality Rates are Declining
Bernatsky S et al, Arth & Rheum; 2006: 2550-2557
![Page 66: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/66.jpg)
Additional Lupus Related Measures
• Aspirin- Known vascular disease SLE + One risk factor Anticardiolipin Ab/LAC
• ACE inhibitors- Prevalent CVD including CHF LVH DM Preferred second drug for hypertension
Wajed J et al Rheumatology 2003
![Page 67: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/67.jpg)
Oral Contraceptives in SLE
• SELENA Trial (Safety of Estrogen in Lupus Erythematosus)– Double-blind non-inferiority, multicenter– OC’s did not increase expected flare rate in mild-
moderate disease1
• Single blind uncontrolled, single center BCP vs IUD (Mexico City)2
– Similar flare rates • Neither study addressed severe active disease
1. Petri, M et al NEJM 2005;353:2550-2558
2. Sanchez-Guerrero J, NEJM, 2005;353:2539-2549
![Page 68: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/68.jpg)
Is Atherosclerosis Increased in SLE?
498 women with SLE at University of Pittsburgh 2208 women in Framingham Offspring Study
Lupus pts 35-44 years: MI 50 x more likely
Risk Factors: Older age at SLE Dx Longer lupus disease duration Longer corticosteroid use Hypercholesterolemia Post menopause
Manzi et al Am J Epidemiol 1997
![Page 69: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/69.jpg)
Is Atherosclerosis Increased in SLE?
Adjusted rates in Canadian SLE pt for baseline traditional risk factors (age, sex, BP, cholesterol, smoking glucose, LVH) using Framingham logistic regression equations
263 SLE patients: 21 MI, 19 CVA, 37 any CVD
Event RR 95%CI
MI 8.3 (4.9-12.4)
CVA 6.7 (3.6-10.9)
Any 5.7 (3.9-7.7)
Esdaile et al Arthritis and Rheum 2001
![Page 70: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/70.jpg)
Histopathologic Classification of Lupus Nephritis
Class I. Minimal mesangial nephritisClass II. Mesangial proliferative nephritisClass III. Focal lupus nephritis (<50% of glomeruli are involved)
A. Active lesions: focal proliferative GN A/C. Active and chronic lesions: focal proliferativ and
sclerosing GN C. Chronic inactive lesions with glomerular scarring: focal
sclerosing GN. Class IV. Diffuse lupus nephritis (>50% of glomeruli are involved)
diffuse segmental (IV-s) type, when only a part of the involved glomeruli are affected
diffuse global GN (IV-G), when the entire glomeruli are affected
IV-S (A), IV-G (A), IV-S (A/C), IV-G (C),IV-S (C),
Class V. Membranous lupus nephritisMay associate with findings characterised in class III/IV.
Class VI. Sclerosing glomerulonephritis90% of glomeruli are sclerotic
![Page 71: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/71.jpg)
Rituximab
• Rituximab is a novel genetically engineered
anti-CD20 therapeutic monoclonal antibody that selectively depletes CD20+ B cells
Shaw et al, 2003: Silverman & Weisman, 2003 – Roche core set
![Page 72: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/72.jpg)
Blys/BAFF
![Page 73: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/73.jpg)
Lupus Rx Algorithm
![Page 74: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/74.jpg)
Crow M, NEJM 2008;359:956-961
![Page 75: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/75.jpg)
SLE Genes: Ethnic DifferencesGENE CAUC AFR references
TNF alpha X Hum Immunol 65:622
16q12-13 X E J Hum Gen 12:668
12q24 X Am J Hum Gen 74:73
FcgRIIIa X Rheum (Ox) 42:446
FcgRIIa X J Clin Invest 95:1348
11p13 (discoid) X J Inv Derm Sym 9:64
NO synth prom X J Rheum 30:60
FasL 1q23 X J Immun 170:132
![Page 76: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/76.jpg)
Arce-Salinas C, Rodrigues-Carcia F, EULAR 2008 THU0234
SLEDAI= SLE Disease Activity Index
![Page 77: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/77.jpg)
Wallace in Arthritis and Allied Conditions, 13th Ed V2, p1319 Koopman, ed
%
YEARS
IMPROVED SURVIVAL IN SLE: 1955-1990
![Page 78: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/78.jpg)
Ideal Risk Factors
• BP- <130/60• LDL-<2.6 mmol/l• Diabetes- FBS < 100
Random BS <110• Smoking- stop!• Obesity- BMI<25kg/m2
Wajed J et al Rheumatology 2003
![Page 79: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/79.jpg)
![Page 80: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/80.jpg)
Rahman A, Isenberg D, NEJM; 2008: 929-039
![Page 81: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/81.jpg)
Lupus nephritis
Class I Minimal mesangial Normal light microscopy; abnormal electron microscopy
Class II Mesangial proliferative
Hypercellular on light microscopy
Class III Focal proliferative <50% glomeruli involved
Class IV Diffuse proliferative >50% glomeruli involved; segmental/global
Class V Membranous Predominantly nephrotic disease
Class VI Advanced sclerosing
Chronic lesions and sclerosis
![Page 82: What’s New in Lupus? Jeffrey Carlin, MD Section Head, Division of Rheumatology Virginia Mason Medical Center Clinical Associate Professor University of](https://reader034.vdocument.in/reader034/viewer/2022052702/56649c7c5503460f94930de2/html5/thumbnails/82.jpg)
Lupus Genetics
• + ANA in general population- 5-15%• Prevalence in 1st degree relative- 10% • Concordance in monozygotic twins- 25%• Concordance in dizygotic twins- 2%